In this study, an intravitreal in situ formingDA-crosslinked hydrogel based on HA and PEG polymers with potentialapplication as a long-acting sustained delivery system for bevacizumaband potentially for other anti-VEGF therapeutics was investigated.The prospect of the system for treating retinal diseases was examinedstep by step by testing hydrogel gelation kinetics, mechanical properties,injectability, biodegradability, sustained release of bevacizumab,and cytocompatibility to retinal cells. This evidence concerns the gene VEGFA and Abnormal retinal morphology.